BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32578333)

  • 21. Differentiation of ovarian serous carcinoma from ovarian clear cell carcinoma using a 10-gene signature selected by comprehensive gene expression analysis.
    Nomura S; Watanabe T; Honma R; Matsukura S; Ito E; Imai JI; Kiko Y; Suzuki O; Hashimoto Y; Kojima M; Furukawa S; Soeda S; Watanabe S; Fujimori K
    Fukushima J Med Sci; 2024 Apr; 70(2):65-73. PubMed ID: 38494731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma.
    Wong OGW; Li J; Cheung ANY
    Front Oncol; 2021; 11():666815. PubMed ID: 34737943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients with stage IA ovarian clear cell carcinoma do not require chemotherapy following surgery.
    Shuqing L; Zhiling Z
    Cancer Med; 2023 Mar; 12(6):6668-6674. PubMed ID: 36416131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CRISPR/Cas9 Screening for Identification of Genes Required for the Growth of Ovarian Clear Cell Carcinoma Cells.
    Kawabata A; Hayashi T; Akasu-Nagayoshi Y; Yamada A; Shimizu N; Yokota N; Nakato R; Shirahige K; Okamoto A; Akiyama T
    Curr Issues Mol Biol; 2022 Apr; 44(4):1587-1596. PubMed ID: 35723366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Application Value of HNF-1β Transcription Factor in the Diagnosis of Ovarian Clear Cell Carcinoma.
    Huang W; Cheng X; Ji J; Zhang J; Li Q
    Int J Gynecol Pathol; 2016 Jan; 35(1):66-71. PubMed ID: 26166716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.
    Ackroyd SA; Arguello D; Ramos P; Mahdi H; ElNaggar A; Winer I; Holloway R; Krivak T; Jones N; Turner VG; Herzog T; Chu C; Brown J; Mantia-Smaldone G
    Gynecol Oncol; 2023 Feb; 169():164-171. PubMed ID: 36333181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype.
    Takenaka M; Köbel M; Garsed DW; Fereday S; Pandey A; Etemadmoghadam D; Hendley J; Kawabata A; Noguchi D; Yanaihara N; Takahashi H; Kiyokawa T; Ikegami M; Takano H; Isonishi S; Ochiai K; Traficante N; Gadipally S; Semple T; Vassiliadis D; Amarasinghe K; Li J; Mir Arnau G; Okamoto A; Friedlander M; Bowtell DDL;
    Clin Cancer Res; 2019 Jul; 25(13):3962-3973. PubMed ID: 30967419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.
    Zhu C; Zhu J; Qian L; Liu H; Shen Z; Wu D; Zhao W; Xiao W; Zhou Y
    BMC Cancer; 2021 Mar; 21(1):322. PubMed ID: 33766002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
    Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
    Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
    [No Abstract]   [Full Text] [Related]  

  • 32. Endometriosis-associated ovarian cancer is not a distinct clinical entity among young patients: A 12-year cohort study.
    Cai Y; Yin J; Jin Y; Li Y; Wu M; Yang J; Huang H; Leng J; Pan L
    Eur J Surg Oncol; 2020 May; 46(5):876-882. PubMed ID: 31837932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors.
    Clemente V; Hoshino A; Shetty M; Nelson A; Erickson BK; Baker R; Rubin N; Khalifa M; Weroha SJ; Lou E; Bazzaro M
    Cancer Res Commun; 2022 Aug; 2(8):784-794. PubMed ID: 36082022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolving population-based statistics for rare epithelial ovarian cancers.
    Matsuo K; Machida H; Matsuzaki S; Grubbs BH; Klar M; Roman LD; Sood AK; Gershenson DM; Wright JD
    Gynecol Oncol; 2020 Apr; 157(1):3-11. PubMed ID: 31954534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The elevated risk of ovarian clear cell carcinoma among Asian Pacific Islander women in the United States is not affected by birthplace.
    Korenaga TR; Ward KK; Saenz C; McHale MT; Plaxe S
    Gynecol Oncol; 2020 Apr; 157(1):62-66. PubMed ID: 32008796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Global gene expression profiling of a mouse model of ovarian clear cell carcinoma caused by ARID1A and PIK3CA mutations implicates a role for inflammatory cytokine signaling.
    Chandler RL; Raab JR; Vernon M; Magnuson T; Schisler JC
    Genom Data; 2015 Sep; 5():329-32. PubMed ID: 26484281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic determinants in patients with uterine and ovarian clear carcinoma.
    Rauh-Hain JA; Winograd D; Growdon WB; Schorge JO; Goodman AK; Boruta DM; Berkowitz RS; Horowitz NS; Del Carmen MG
    Gynecol Oncol; 2012 May; 125(2):376-80. PubMed ID: 22366593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of hepatocyte nuclear factor-1β as a diagnostic marker in ovarian carcinomas with clear cells.
    Kao YC; Lin MC; Lin WC; Jeng YM; Mao TL
    Histopathology; 2012 Nov; 61(5):760-8. PubMed ID: 22747504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma.
    Takahashi K; Takenaka M; Okamoto A; Bowtell DDL; Kohno T
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33917230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring the cellular and molecular differences between ovarian clear cell carcinoma and high-grade serous carcinoma using single-cell RNA sequencing and GEO gene expression signatures.
    Guo D; Zhang S; Gao Y; Shi J; Wang X; Zhang Z; Zhang Y; Wang Y; Zhao K; Li M; Wang A; Wang P; Gou Y; Zhang M; Liu M; Zhang Y; Chen R; Sun J; Wang S; Wu X; Liang Z; Chen J; Lang J
    Cell Biosci; 2023 Jul; 13(1):139. PubMed ID: 37525249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.